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OBJECTIVES: To determine the role of impaired func-
tional status as a risk factor for severe Clostridium difficile
infection (CDI) in older adults.
DESIGN: Prospective cohort study.
SETTING: University of Michigan Health System, a
930-bed tertiary care hospital.
PARTICIPANTS: Hospitalized individuals with CDI aged
50 and older.
MEASUREMENTS: Demographic and clinical character-
istics and a composite outcome, CDI severity score: fever
(>38°C), acute organ dysfunction, white blood cell count
greater than 15,000/lL, lack of response to therapy, inten-
sive care unit admission, need for colectomy, or death
from CDI. Preadmission functional status was assessed
according to ability to perform activities of daily living
(ADLs); participants were assigned to an ADL class (inde-
pendent, some assistance, full assistance). Secondary out-
comes included length of stay, 90-day mortality and
readmission, and CDI recurrence.
RESULTS: Ninety hospitalized individuals with CDI were
identified (mean age 66.6  10.2); 58 (64.4%) had severe
CDI as measured according to a positive severity score. At
baseline, 25 (27.8%) required assistance with ADLs. On
univariate analysis, ADL class of full assistance was associ-
ated with a positive severity score (odds ratio (OR) = 7,
95% confidence interval (CI) = 1.83–26.79, P = .004). In
a multivariable model including age, ADL class, congestive
heart failure, diabetes mellitus, depression, weighted
Charlson-Deyo comorbidity score, immunosuppression,
prior CDI, and proton pump inhibitor use, an ADL class
of full assistance retained its association with a positive
severity score (OR = 8.1, 95% CI = 1.24–52.95, P = .03).
ADL class was not associated with secondary outcomes.
CONCLUSION: In this cohort of hospitalized older
adults, impaired functional status was an independent risk
factor for severe CDI. J Am Geriatr Soc 61:1738–1742,
2013.
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In recent years, Clostridium difficile infection (CDI) hasemerged as a major source of morbidity and mortality in
hospitalized older adults.1–6 The clinical manifestations of
CDI vary, ranging from self-limited diarrheal illness to ful-
minant and even fatal pseudomembranous colitis and toxic
megacolon.7,8 Although toxin production is essential to
the pathophysiology of CDI,9–12 it remains unclear why
some individuals experience severe disease. Previous work
has identified numerous risk factors for severe CDI, includ-
ing older age13 and comorbid conditions.14–16 In addition
to age, the role of poor functional status is increasingly
recognized as an important and independent risk factor for
poor outcomes in older adults with infection.17–20
The relationship between CDI and functional status
was explored in a study that demonstrated that impaired
functional status, according to lower Barthel scores,21 was
associated with more-severe disease,22 but Barthel scores
were not included in the authors’ final multivariate
model, because these scores were highly correlated with
abbreviated mental test (AMT) scores, and the authors
chose to include AMT scores in lieu of the Barthel scores.
This prevented any firm conclusions about whether
impaired functional status is an independent risk factor
for severe CDI.
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Although the identification of risk factors associated
with severe CDI has important implications in the manage-
ment of individuals, the lack of a single consensus defini-
tion complicates the concept of severity itself. Investigators
must select from a myriad of classification systems pub-
lished in the literature or devise their own severity defini-
tion. One study23 endorsed a surveillance definition of
severe CDI that focuses on outcomes attributable to CDI,
including, within 30 days of diagnosis, admission to an
intensive care unit (ICU), the need for surgery (such as
colectomy), or death. The Society for Healthcare Epidemi-
ology of America and the Infectious Diseases Society of
America 2010 clinical practice guidelines24 recommend
using clinical criteria present at the time of diagnosis: leu-
kocytosis (white blood cell (WBC) count ≥15 000 cells/lL),
a 1.5-fold rise in serum creatinine, hypotension or shock,
ileus, or megacolon. A systematic review25 identified
seven sets of criteria used to measure CDI severity or pre-
dict treatment outcomes, using combinations of 17 clini-
cal variables including diarrhea frequency, leukocytosis,
fever, hypotension, and renal insufficiency. The current
study sought to explore the relationship between func-
tional status and CDI severity, applying a definition that
includes individual outcomes and clinical criteria readily




The University of Michigan Health System is a 930-bed
tertiary care facility with a comprehensive electronic medi-
cal record. Using microbiology records to identify potential
subjects, hospitalized adults with diarrhea and a positive
C. difficile test between October 2010 and May 2012 were
prospectively enrolled. Given the interest in the association
between impaired functional status and CDI severity, it
was decided to limit this analysis to the subset of individu-
als aged 50 and older. The University of Michigan institu-
tional review board approved this study; all subjects
provided written informed consent.
Microbiology
Clostridium difficile testing included the C. DIFF QUIK
CHEK COMPLETE test for glutamate dehydrogenase
(GDH) and toxins A or B (Techlab, Inc., Blacksburg, VA).
All GDH-positive and/toxin-negative stools were analyzed
further using the tcdB gene using real-time polymerase
chain reaction (BD GeneOhm Cdiff Assay, Franklin Lakes,
NJ). Positive tests were confirmed according to anaerobic
culture as described previously.26
Clinical Characteristics
Participant medical records were reviewed, and clinical
characteristics of interest were recorded, including immu-
nosuppression (innate or exogenous); acute organ dysfunc-
tion (AOD); lack of response to initial CDI therapy
(defined as a change in initial therapy or a lack of clinical
response within 5 days); and ICU admission, colectomy, or
death attributable to CDI within 30 days. The definition
for lack of clinical response was based on the Infectious
Diseases Society of America clinical practice guidelines,24
which referenced a previous study27 and a subsequent
study.6 AOD was defined as acute kidney injury according
to the RIFLE criteria (risk, injury, failure, loss, end-stage
renal disease),28 acute respiratory distress syndrome
(recorded in the chart or a ration of partial pressure of
oxygen in arterial blood to fraction of inspired oxygen
<200 and diffuse pulmonary infiltrates with acute onset),
new or worse heart failure (recorded in the chart), liver
failure (new or worse coagulopathy or hepatic encephalop-
athy), or shock (systolic blood pressure <90 mmHg or
need for pressors or inotropes). Two reviewers (DM, EC)
independently abstracted data from participant charts, and
a third reviewer (KR) resolved differences.
Data were collected at the time of study enrollment
on age, sex, proton pump inhibitor (PPI) use, and tempera-
ture and maximum white blood cell (WBC) count within
24 hours of CDI diagnosis. Information on length of stay
and 90-day mortality or readmission was obtained from
the electronic medical record. CDI recurrence was defined
as recurrent diarrhea and repeat positive assay more than
14 days from the original diagnosis.
Upon enrollment, interviews were conducted with the
participants or their families to obtain information on co-
morbid conditions such as chronic kidney disease, conges-
tive heart failure (CHF), diabetes mellitus (DM), and prior
CDI and baseline functional status. Ability to perform
activities of daily living (ADLs)—bathing, transferring,
walking, dressing, grooming, and feeding, independently or
with assistance—was asked about. These were assessed at
the time of the participant’s enrollment (baseline), before
the hospitalization, and at the onset of CDI. Overall func-
tional status was characterized as independent (no assis-
tance needed for any ADL), some assistance (assistance
needed in 1–5 ADLs), or full assistance (assistance needed
in all 6 ADLs). The participant’s living arrangements and
care needs (living independently at home, living at home
with skilled nursing services, or residing in an extended care
facility (ECF)) before admission was also asked about.
Information about discharge location and need for home
care services was obtained from the medical record.
The presence of comorbid illness was also assessed
using International Classification of Diseases, Ninth Revi-
sion (ICD-9) codes as described previously.29 Weights from
the original Charlson Comorbidity Index30 were assigned
to the individual variables in the Deyo modification of the
Charlson score to create a weighted Charlson-Deyo comor-
bidity index. ICD-9 code data and participant enrollment
interviews were combined to maximize sensitivity.
Data Analysis
To assess the relationship between diminished functional
status and severe CDI, a binary variable called severity
score was defined that was true (positive) if any of the fol-
lowing CDI severity markers were present: WBC count
greater than 15,000 cells/lL; fever (temperature >38°C);
AOD; no initial response to therapy; and ICU admission,
colectomy, or death attributable to CDI within 30 days of
presentation.
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Univariate analysis using simple logistic regression
identified risk factors for positive severity score and tested
whether ADL class was associated with positive severity
score. A two-tailed P-value ≤.05 was considered statisti-
cally significant. Variables that were significant in univari-
ate analysis and variables that had a priori clinical
significance were analyzed using multivariable logistic
regression.
The association between ADL class and the secondary
outcomes of need for readmission and 90-day mortality
was also explored. The association between impaired func-
tional status and CDI recurrence was examined using Kap-
lan–Meier survival analysis. Chi-square and Fisher exact
tests were used to compare proportions for categorical
variables. The Student t-test was used to compare continu-
ous variables including length of stay. All values are
expressed as means  standard deviations. Crude odds
ratios (ORs) and 95% confidence intervals (CI) were cal-
culated. Statistical analysis was conducted using R 2.15.0
(http://www.r-project.org), SAS version 9.3 (SAS Institute,
Inc., Cary, NC), and Graphpad Prism 5.04 (Graphpad
Software, Inc., La Jolla, CA).
RESULTS
Ninety individuals (mean age 66.6  10.2) met criteria for
inclusion in the study. Fifty-two were female (57.8%).
Common medical comorbidities were diabetes mellitus
(31.1%), CHF (25.6%), depression (24.4%), and immuno-
suppression (34.4%) (Table 1). CDI had previously been
diagnosed in 18 (20%), and 63 (70%) were using PPIs at
the time of diagnosis (Table 1).
Sixty-five participants (72.2%) had no impairments in
physical function (independent in ADLs); of the remaining
25 participants with poor functional status, eight needed
some assistance, and 17 needed full assistance with ADLs
(Table 1). Fifty-eight participants (64.4%) had at least one
CDI severity marker (positive severity score): most com-
monly, WBC count greater than 15,000/lL (24), lack of
response to initial therapy (22), AOD (14), and ICU
admission (5) or death (2) due to CDI (Online Appendix—
Figure S1).
Univariate analysis identified several factors associated
with severe CDI, including age, history of depression,
needing full assistance with ADLs, and ECF residence
(Table 2). Needing assistance with each individual ADL
was also associated with severe CDI, although an associa-
tion was not found between an ADL class of some assis-
tance and severe CDI (Table 2).
The final multivariable model for severe CDI included
age, ADL class, CHF, DM, depression, weighted Charlson-
Deyo comorbidity score, immunosuppression, prior CDI,
and PPI use. ECF residence and individual ADLs were
excluded from the final model to avoid multicollinearity
with ADL class (Table 3). An ADL class of full assistance
retained its association with a positive severity score in the
presence of these other covariates (OR = 8.1, 95%
CI = 1.24–52.98, P = .03). There was also an association
with age (OR = 1.07, 95% CI = 1.01–1.13, P = .03), DM
(OR = 0.22, 95% CI = 0.06–0.74, P = .01), and depres-
sion (OR = 5.04, 95% CI = 1.27–19.97, P = .02).
No association was found between ADL class and the
secondary outcomes of length of stay, 90-day mortality, or
90-day readmission (data not shown). Kaplan–Meier sur-
vival analysis for recurrent CDI comparing participants
according to ADL class found greater risk for needing
some assistance (hazard ratio (HR) = 2.46, 95%
CI = 0.82–7.37, P = .11) and full assistance (HR = 1.69,
95% CI = 0.75–3.82, P = .20), but these results did not
reach significance (Online Appendix—Figure S2).
DISCUSSION
The lack of ability to predict accurately, at the earliest
stages of illness, which individuals with CDI will progress
to severe disease and experience adverse clinical outcomes
remains an important limitation to optimal management.
Such knowledge could affect resource allocation and
inform early treatment decisions, with the potential to
improve outcomes. For example, the decision to use
vancomycin, which is recommended for severe CDI (WBC
count >15,000 cells/lL or serum creatinine level >1.5
times the premorbid level),24 in lieu of metronidazole may
be appropriate in individuals with greater risk of poor out-
comes.
Table 1. Characteristics of Participants Aged 50 and
Older with Clostridium difficile Infection (CDI)
(N = 90)
Characteristic Value
Age, mean  standard deviation 66.6  10.2
Female, n (%) 52 (57.8)
ADL class, n (%)
Independent 65 (72.2)
Some assistancea 8 (8.9)
Full assistanceb 17 (18.9)
Assistance with feeding, n (%) 21 (23.3)
Assistance with walking, n (%) 23 (25.6)
Assistance with moving, n (%) 19 (21.1)
Assistance with dressing, n (%) 22 (24.4)
Assistance with grooming, n (%) 23 (25.6)
Assistance with bathing, n (%) 22 (24.4)
Extended care facility residence, n (%) 15 (16.7)
Proton pump inhibitor use, n (%) 63 (70)
Prior CDI, n (%) 18 (20)
Weighted Charlson-Deyo score, mean  SD 3.8  2.4
Dementia, n (%) 3 (3.3)
Diabetes mellitus, n (%) 28 (31.1)
Congestive heart failure, n (%) 23 (25.6)
Chronic kidney disease, n (%) 24 (26.7)
Depression, n (%) 22 (24.4)
Cancer, n (%) 50 (55.6)
Stroke, n (%) 23 (25.6)
Immunosuppression, n (%) 31 (34.4)
Outcome, n (%)
Positive severity scorec 58 (64.4)
90-day readmission 47 (52.2)
90-day mortality 8 (8.9)
aAssistance needed for 1–5 activities of daily living (ADLs).
bAssistance needed for all 6 ADLs.
cMarkers of severe CDI: fever; white blood cell count >15,000 cells/lL;
acute organ dysfunction; no response to therapy; or intensive care unit
admission, colectomy, or death from CDI within 30 days.
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Older adults are at higher risk of poorer outcomes
resulting from certain infections,17–19 in part because of an
impaired immune response, and CDI fits within this para-
digm.21 The preceding results suggest that, in addition to
age, impaired functional status is an independent predictor
of severe CDI, as demonstrated by the final multivariable
model, which adjusted for the potential confounding
effects of comorbid disease, immunosuppression, and PPI
use. Although it was not possible to demonstrate the same
connection in participants who needed some assistance,
the lack of an association may be because of type II error,
because only eight participants fell into this category.
There is a critical need for better tools to predict severe
CDI; these findings suggest that measurement of functional
status may have a role in robust clinical risk prediction
algorithms. No greater risk of recurrent disease was found
in participants with impaired functional status, but this
may also have been because of type II error.
A puzzling result of the present study is that DM
appeared to be protective against severe CDI in the final mul-
tivariable model. One possible explanation is that impaired
neutrophil chemotaxis and antibacterial activities may lead
to fewer individuals with diabetes mellitus presenting with
fever or leukocytosis,31 although testing this hypothesis was
beyond the scope of the study. Furthermore, a strong body
of clinical evidence does not support the classically held
dogma that DM is associated with greater susceptibility to
infection and poor outcomes from infection.32 Similar to the
unexpected finding, in an analysis of the Nationwide Inpa-
tient Sample, a diagnosis of DM was associated with less
mortality from CDI.33 Also interesting is the strong associa-
tion between depression and severe CDI observed. Similarly,
a previous study found an association between antidepres-
sant use and the risk of developing CDI.34 Further study is
required to explore these intriguing relationships.
A limitation of this work is the lack of validated
frailty measures, which may have an effect on the risk of
severe disease and other adverse outcomes independent of
the contribution from impaired functional status. Similarly,
data on impaired cognitive function or delirium during
hospitalization were not captured, so it was not possible
to account for any contribution from these potential risk
factors. Future studies should explore the influence of these
factors on the development of severe CDI and clinical
outcomes.
In summary, this study offers additional insights into
the complex interplay between age, comorbid disease,
functional status, and the risk of severe CDI and suggests
that impaired functional status is an independent risk fac-
tor for development of severe CDI. Future studies could
include validation of these findings in a larger cohort of
mostly older adults with severe CDI, incorporation of
functional status into a broader risk-prediction model with
clinical and biochemical predictors of severity, and a pro-
spective trial in which a risk-based clinical algorithm
guides treatment decisions.
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Table 2. Univariate Logistic Regression for Severity
Score
Variable
Odds Ratio (95% Confidence
Interval) P-Value
Age 1.07 (1.02–1.12) .005
Female 0.75 (0.32–1.74) .50
ADL class
Some assistancea 4.50 (0.84–24.04) .08
Full assistanceb 7.00 (1.83–26.79) .004
Assistance with feeding 5.86 (1.78–19.26) .004
Assistance with walking 5.01 (1.66–15.11) .004
Assistance with moving 7.29 (1.95–27.28) .003
Assistance with dressing 6.43 (1.96–21.05) .002
Assistance with grooming 5.01 (1.66–15.11) .004
Assistance with bathing 4.57 (1.51–13.83) .007
Extended care facility residence 8.27 (1.74–39.25) .008
Proton pump inhibitor use 1.82 (0.73–4.54) .20
Prior CDI 2.24 (0.76–6.61) .15
Weighted Charlson-Deyo score 1.12 (0.94–1.34) .19
Dementia N/A (N/A) .97
Diabetes mellitus 0.40 (0.16–1.01) .05
Congestive heart failure 1.06 (0.41–2.73) .91
Chronic kidney disease 1.18 (0.46–1.62) .73
Depression 3.38 (1.18–9.68) .02
Cancer 1.56 (0.67–3.59) .30
Stroke 1.06 (0.41–2.73) .91
Immunosuppression 0.69 (0.29–1.66) .41
Markers of severe Clostridium difficile infection (CDI): fever; white blood
cell count >15,000 cells/lL; acute organ dysfunction; no response to ther-
apy; and intensive care unit admission, colectomy, or death from CDI
within 30 days.
aAssistance needed for 1–5 activities of daily living (ADLs).
bAssistance needed for all 6 ADLs.
N/A = not available.
Table 3. Multiple Logistic Regression for Severity
Score
Variable
Odds Ratio (95% Confidence
Interval) P-Value
Age 1.07 (1.01–1.13) .03
ADL class
Some assistancea 4.54 (0.56–37.07) .16
Full assistanceb 8.10 (1.24–52.95) .03
Proton pump inhibitor use 3.10 (0.86–11.18) .08
Prior CDI 1.98 (0.43–9.13) .38
Weighted Charlson-Deyo score 1.26 (0.98–1.62) .07
Congestive heart failure 0.26 (0.06–1.13) .07
Diabetes mellitus 0.22 (0.06–0.75) .01
Depression 5.03 (1.27–19.96) .02
Immunosuppression 0.72 (0.24–2.18) .56
Markers of severe Clostridium difficile infection (CDI): fever; white blood
cell count >15,000 cells/lL; acute organ dysfunction; no response to ther-
apy; and intensive care unit admission, colectomy, or death from CDI
within 30 days.
aAssistance needed for 1–5 activities of daily living (ADLs).
bAssistance needed for all 6 ADLs.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Presence of Clostridium difficile infection
(CDI) severity markers (fever (>38°C); acute organ dys-
function (AOD); white blood cell count (WBC) in cells/lL;
no response to CDI therapy; and outcomes attributable to
CDI within 30 days—intensive care unit (ICU) admission,
colectomy, and death).
Figure S2. Kaplan–Meier survival curve for Clostrid-
ium difficile infection (CDI) recurrence. This figure com-
pares the risk of recurrent CDI in participants who were
independent in activities of daily living, those who needed
some assistance (hazard ratio (HR) = 2.46, 95% confi-
dence interval (CI) = 0.82–7.37, P = .11), and those who
needed full assistance (HR = 1.69, 95% CI = 0.75–3.82,
P = .20).
Please note: Wiley Blackwell is not responsible for the
content, accuracy, errors, or functionality of any support-
ing materials supplied by the authors. Any queries (other
than missing material) should be directed to the
corresponding author for the article.
1742 RAO ET AL. OCTOBER 2013–VOL. 61, NO. 10 JAGS
